Bumetanide to Treat Parkinson Disease: A Report of 4 Cases.
Identifieur interne : 000215 ( PubMed/Corpus ); précédent : 000214; suivant : 000216Bumetanide to Treat Parkinson Disease: A Report of 4 Cases.
Auteurs : Philippe Damier ; Constance Hammond ; Yeheskel Ben-AriSource :
- Clinical neuropharmacology [ 1537-162X ]
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Bumetanide, Sodium Potassium Chloride Symporter Inhibitors.
- drug therapy : Parkinson Disease.
- Aged, Female, Humans, Male, Middle Aged.
Abstract
Relying on recent experimental data in 2 animal models of Parkinson disease (PD), we have tested the effects of the loop diuretic bumetanide as an add-on treatment to dopaminergic drugs in 4 volunteered patients with PD using the Unified Parkinson's Disease Rating Scale. Bumetanide is a specific antagonist of the chloride importer NKCC1 (sodium/potassium/chloride cotransporter isoform 1) that ameliorates neuronal inhibition by reducing intracellular chloride levels in a variety of pathological conditions. Bumetanide is however not labeled for use in PD. We report an improvement of PD motor symptoms in the 4 patients treated with bumetanide (5 mg/d for 2 months). Bumetanide also improved gait and freezing in 2 of these patients. Our results suggest that bumetanide is well tolerated and call for double-blind, placebo-controlled, randomized trials to confirm the therapeutic efficacy of bumetanide.
DOI: 10.1097/WNF.0000000000000114
PubMed: 26757306
Links to Exploration step
pubmed:26757306Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Bumetanide to Treat Parkinson Disease: A Report of 4 Cases.</title><author><name sortKey="Damier, Philippe" sort="Damier, Philippe" uniqKey="Damier P" first="Philippe" last="Damier">Philippe Damier</name><affiliation><nlm:affiliation>*CHU Nantes, Nantes; and †INMED, INSERM U 901 and B&A Therapeutics, Campus Scientifique de Luminy, Marseille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Hammond, Constance" sort="Hammond, Constance" uniqKey="Hammond C" first="Constance" last="Hammond">Constance Hammond</name></author><author><name sortKey="Ben Ari, Yeheskel" sort="Ben Ari, Yeheskel" uniqKey="Ben Ari Y" first="Yeheskel" last="Ben-Ari">Yeheskel Ben-Ari</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>2016 Jan-Feb</MedlineDate></PubDate></date><idno type="RBID">pubmed:26757306</idno><idno type="pmid">26757306</idno><idno type="doi">10.1097/WNF.0000000000000114</idno><idno type="wicri:Area/PubMed/Corpus">000215</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000215</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Bumetanide to Treat Parkinson Disease: A Report of 4 Cases.</title><author><name sortKey="Damier, Philippe" sort="Damier, Philippe" uniqKey="Damier P" first="Philippe" last="Damier">Philippe Damier</name><affiliation><nlm:affiliation>*CHU Nantes, Nantes; and †INMED, INSERM U 901 and B&A Therapeutics, Campus Scientifique de Luminy, Marseille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Hammond, Constance" sort="Hammond, Constance" uniqKey="Hammond C" first="Constance" last="Hammond">Constance Hammond</name></author><author><name sortKey="Ben Ari, Yeheskel" sort="Ben Ari, Yeheskel" uniqKey="Ben Ari Y" first="Yeheskel" last="Ben-Ari">Yeheskel Ben-Ari</name></author></analytic><series><title level="j">Clinical neuropharmacology</title><idno type="eISSN">1537-162X</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Bumetanide (therapeutic use)</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Sodium Potassium Chloride Symporter Inhibitors (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Bumetanide</term><term>Sodium Potassium Chloride Symporter Inhibitors</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Relying on recent experimental data in 2 animal models of Parkinson disease (PD), we have tested the effects of the loop diuretic bumetanide as an add-on treatment to dopaminergic drugs in 4 volunteered patients with PD using the Unified Parkinson's Disease Rating Scale. Bumetanide is a specific antagonist of the chloride importer NKCC1 (sodium/potassium/chloride cotransporter isoform 1) that ameliorates neuronal inhibition by reducing intracellular chloride levels in a variety of pathological conditions. Bumetanide is however not labeled for use in PD. We report an improvement of PD motor symptoms in the 4 patients treated with bumetanide (5 mg/d for 2 months). Bumetanide also improved gait and freezing in 2 of these patients. Our results suggest that bumetanide is well tolerated and call for double-blind, placebo-controlled, randomized trials to confirm the therapeutic efficacy of bumetanide.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26757306</PMID><DateCreated><Year>2016</Year><Month>01</Month><Day>15</Day></DateCreated><DateCompleted><Year>2016</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-162X</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>1</Issue><PubDate><MedlineDate>2016 Jan-Feb</MedlineDate></PubDate></JournalIssue><Title>Clinical neuropharmacology</Title><ISOAbbreviation>Clin Neuropharmacol</ISOAbbreviation></Journal><ArticleTitle>Bumetanide to Treat Parkinson Disease: A Report of 4 Cases.</ArticleTitle><Pagination><MedlinePgn>57-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/WNF.0000000000000114</ELocationID><Abstract><AbstractText>Relying on recent experimental data in 2 animal models of Parkinson disease (PD), we have tested the effects of the loop diuretic bumetanide as an add-on treatment to dopaminergic drugs in 4 volunteered patients with PD using the Unified Parkinson's Disease Rating Scale. Bumetanide is a specific antagonist of the chloride importer NKCC1 (sodium/potassium/chloride cotransporter isoform 1) that ameliorates neuronal inhibition by reducing intracellular chloride levels in a variety of pathological conditions. Bumetanide is however not labeled for use in PD. We report an improvement of PD motor symptoms in the 4 patients treated with bumetanide (5 mg/d for 2 months). Bumetanide also improved gait and freezing in 2 of these patients. Our results suggest that bumetanide is well tolerated and call for double-blind, placebo-controlled, randomized trials to confirm the therapeutic efficacy of bumetanide.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Damier</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>*CHU Nantes, Nantes; and †INMED, INSERM U 901 and B&A Therapeutics, Campus Scientifique de Luminy, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hammond</LastName><ForeName>Constance</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Ben-Ari</LastName><ForeName>Yeheskel</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Neuropharmacol</MedlineTA><NlmUniqueID>7607910</NlmUniqueID><ISSNLinking>0362-5664</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D049994">Sodium Potassium Chloride Symporter Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Y2S3XUQ5H</RegistryNumber><NameOfSubstance UI="D002034">Bumetanide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002034" MajorTopicYN="N">Bumetanide</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049994" MajorTopicYN="N">Sodium Potassium Chloride Symporter Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26757306</ArticleId><ArticleId IdType="doi">10.1097/WNF.0000000000000114</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000215 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000215 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:26757306
|texte= Bumetanide to Treat Parkinson Disease: A Report of 4 Cases.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:26757306" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |